ArticlePloS one2019
In vivo activity and low toxicity of the second-generation antimicrobial peptide DGL13K.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 64 citations in OpenAlex.
- The surveillance of antimicrobial resistance in wastewater from a one health perspective: A global scoping and temporal review (2014-2024).One health (Amsterdam, Netherlands) · 2025Article
- A Serum-Stable Antimicrobial Peptide-Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeted Modification of the Antimicrobial Peptide DGL13K Reveals a Naturally Optimized Sequence for Topical Applications.Microorganisms · 2025Article
- Resisting the resistance: the antimicrobial peptide DGL13K selects for small colony variants ofJournal of bacteriology · 2025Article
- Phage-Encoded Antimicrobial Peptide gp28 Demonstrates LL-37-Like Antimicrobial Activity Against Multidrug-ResistantPHAGE (New Rochelle, N.Y.) · 2025Article
- Identification and characterization of amphipathic antimicrobial peptides with broad spectrum activity against multi-drug resistant bacteria.Current research in microbial sciences · 2025Article
- Understanding the pathophysiology ofBurns & trauma · 2025Review
- Green Synthesis of Silver Nanoparticle fromAntibiotics (Basel, Switzerland) · 2024Article
- The oral pathogen Porphyromonas gingivalis gains tolerance to the antimicrobial peptide DGL13K by synonymous mutations in hagA.PloS one · 2024Article
- Exploration of Antimicrobial Peptides in the Treatment of Gentamicin-ResistantInfection and drug resistance · 2024Article
- Chemoselective Coatings of GL13K Antimicrobial Peptides for Dental Implants.Pharmaceutics · 2023Article
- Novel D-form of hybrid peptide (D-AP19) rapidly kills Acinetobacter baumannii while tolerating proteolytic enzymes.Scientific reports · 2022Article
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Neuroprotective effects on microglia and insights into the structure-activity relationship of an antioxidant peptide isolated from Pelophylax perezi.Journal of cellular and molecular medicine · 2022Article
- Antimicrobial Random Peptide Mixtures EradicateAntibiotics (Basel, Switzerland) · 2022Article
- Hybrid nanocoatings of self-assembled organic-inorganic amphiphiles for prevention of implant infections.Acta biomaterialia · 2022Article
- Challenges and innovations in treating chronic and acute wound infections: from basic science to clinical practice.Burns & trauma · 2022Review
- Interactions of two enantiomers of a designer antimicrobial peptide with structural components of the bacterial cell envelope.Journal of peptide science : an official publication of the European Peptide Society · 2022Article
- Article
- Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV.Advanced therapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Antimicrobial peptides have been evaluated as possible alternatives to traditional antibiotics. The translational potential of the antimicrobial peptide DGL13K was tested with focus on peptide toxicity and in vivo activity in two animal models. DGL13K was effective against Pseudomonas aeruginosa, Staphylococcus aureus and methicillin-resistant S. aureus with minimal bactericidal concentrations similar to the minimal inhibitory concentration. The peptide showed low toxicity to human red blood cells and HEK cells with median lethal dose around 1 mg/ml. The median lethal dose in greater wax moth larvae (Galleria mellonella) was about 125mg/kg while the peptide caused no skin toxicity in a mouse model. A novel high-throughput luminescence assay was used to test peptide activity in infected G. mellonella, thus reducing vertebrate animal use. DGL13K killed P. aeruginosa in both the G. mellonella model and a mouse burn wound infection model, with bacterial viability 3-10-fold lower than in untreated controls. Future experiments will focus on optimizing peptide delivery, dose and frequency to further improve the antibacterial effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.